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Background: Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1
study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies.
Methods: Advanced solid tumor patients received oral MK-2206 45 or 60 mg (QOD) with either carboplatin
(AUC 6.0) and paclitaxel 200 mg/m2 (arm 1), docetaxel 75 mg/m2 (arm 2), or erlotinib 100 or 150 mg daily (arm 3);
alternative schedules of MK-2206 135-200 mg QW or 90-250 mg Q3W were also tested.
Results: MTD of MK-2206 (N = 72) was 45 mg QOD or 200 mg Q3W (arm 1); MAD was 200 mg Q3W (arm 2) and
135 mg QW (arm 3). DLTs included skin rash (arms 1, 3), febrile neutropenia (QOD, arms 1, 2), tinnitus (Q3W, arm 2),
and stomatitis (QOD, arm 3). Common drug-related toxicities included fatigue (68%), nausea (49%), and rash (47%).
Two patients with squamous cell carcinoma of the head and neck (arm 1; Q3W) demonstrated a complete and
partial response (PR); additional PRs were observed in patients (1 each) with melanoma, endometrial, neuroendocrine
prostate, NSCLC, and cervical cancers. Six patients had stable disease ≥6 months.
Conclusion: MK-2206 plus carboplatin and paclitaxel, docetaxel, or erlotinib was well-tolerated, with early evidence of
antitumor activity.
Trial registration: ClinicalTrials.gov: NCT00848718.
Keywords: MK-2206, AKT inhibitor, Protein serine-threonine kinase, Phase 1, Chemotherapy, Combination therapy,
Solid tumorsIntroduction
The phosphatidylinositide 3-kinase (PI3K)/AKT/mam-
malian target of rapamycin (mTOR) signaling pathway is
a critical driver of tumor progression [1]. Hyperactivation
of this pathway is an important driver of malignant pro-
gression via increased cancer cell growth, survival, and
metabolism, as well as chemoresistance [2,3]. Hyperactiva-
tion may occur through different mechanisms, including
upstream stimulation by receptor tyrosine kinases,
PIK3CA and AKT mutations or amplifications, and loss of
PTEN function [4]. In view of the key role of the PI3K/* Correspondence: rhoda.molife@icr.ac.uk
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stated.AKT/mTOR pathway in cancer, multiple strategies have
been developed in recent years to target critical compo-
nents of this signaling cascade [5-7]. AKT (protein kinase
B [PKB]), a serine/threonine kinase, is directly activated in
response to PI3K and is a major effector of PI3K in can-
cers [8-10]. There are 3 different protein isoforms, AKT1,
AKT2, and AKT3, with overlapping and distinct roles in
cancer; for example, AKT1 promotes cellular survival and
growth [11]. In addition, AKT activation and overexpres-
sion are commonly associated with chemo- and radio-
resistance [2,12], and dominant-negative mutants of AKT
have been shown to enhance the activity of chemothera-
peutics [13,14].
Adenosine triphosphate (ATP) competitive and allo-
steric classes of small-molecule AKT inhibitors withtd. This is an Open Access article distributed under the terms of the Creative
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isoforms have been developed [5,7]. One member of the
allosteric class is MK-2206 (Merck & Co., Inc., Whitehouse
Station, NJ, USA), an oral, highly selective inhibitor of
AKT that binds at a site in the pleckstrin-homology (PH)
domain, distinct from the ATP-binding pocket, resulting
in a conformational change that prevents the localization
of AKT to the plasma membrane and its subsequent acti-
vation [15,16]. It displays nanomolar (nM) potency against
all 3 AKT isoforms (AKT1, half maximal inhibitory con-
centration [IC50] = 5 nM; AKT2, IC50 = 12 nM; AKT3,
IC50 = 65 nM) [16]. A first-in-human phase 1 combi-
nation study defined the maximum tolerated dose (MTD),
pharmacokinetics (PK), and pharmacodynamics (PD) of
an alternate day (QOD) and weekly (QW) schedule of
MK-2206 in patients with advanced solid tumors [17,18].
The dose-limiting toxicities (DLT) were rash and stoma-
titis. The PK profile was dose proportional, and PD ana-
lysis of both schedules demonstrated the downstream
effects of AKT inhibition with a significant decline in
phosphorylated AKT (pAKT; ser473) in post-treatment
tumor biopsies, and in pPRAS40 (rhr246) in hair follicles.
Reversible hyperglycemia and an increase in insulin
c-peptide further confirmed target modulation. Minor re-
sponses were demonstrated in 2 patients with neuroendo-
crine pancreatic cancers and 1 patient with pancreatic
adenocarcinoma and PTEN loss (in addition to KRAS
G12D mutation).
In preclinical models, MK-2206 enhanced the activity of
conventional cytotoxics and other molecularly targeted
therapies [19]. In vitro, MK-2206 demonstrated synergy
with both erlotinib and lapatinib in inhibiting proliferation
and inducing apoptosis of non-small cell lung (NSCLC)
cell lines, including those that were RAS mutant, and
breast cancer cell lines. Although treatment with erlotinib
inhibited EGFR and pERK phosphorylation of the RAF-
RAS-MEK pathway in the A431 cell line and mouse NCI-
H292 tumor xenografts, there was no effect on pAKT and
pRAS40, downstream markers of AKT inhibition. How-
ever, the combination with MK-2206 resulted in decreased
levels of pAKT and pRAS40. The inhibition of both path-
ways led to more profound inhibition of pGSK3b and pS6,
which are downstream signaling proteins that correlate
with cell growth and survival. The combination also
demonstrated significantly greater in vivo tumor growth
suppression and tumor regressions over each single agent
using both a 3 times per week and QW schedule of
MK-2206 in the mouse tumor xenografts.
In vitro, MK-2206 demonstrated synergy with several
conventional cytotoxics, including carboplatin and doce-
taxel, in inhibiting the growth of NCI-H292 and A2780
tumor cells [19]. Carboplatin-induced apoptosis was also
enhanced by MK-2206 in a sequence-dependent manner:
concurrent treatment or pretreatment with carboplatininduced A2780 cell death in a dose-dependent man-
ner, whereas pretreatment with MK-2206 did not. In
vivo, MK-2206 synergised with docetaxel, carboplatin,
and gemcitabine in inhibiting the growth of PC-3
prostate and NCI-H462 tumor xenografts with a
similar-sequence dependent pattern as for carboplatin
in vitro.
On this background, a multi-arm phase 1 dose-escalation
study of MK-2206 in combination with carboplatin and
paclitaxel, docetaxel, or erlotinib in patients with
advanced solid tumors was initiated. The primary objec-
tives were to evaluate safety and tolerability, DLTs, and
the MTD/recommended phase 2 dose (RP2D) of MK-
2206 when administered orally (PO) in the above combi-
nations. Additional objectives were to explore the PK
profile, antitumor activity of MK-2206 in combination
and correlation of anti-tumor activity with tumor P13K
pathway activation events.Materials and methods
This phase 1, multi-arm, open-label, dose-escalation study
(ClinicalTrials.gov: NCT00848718; http://clinicaltrials.gov/
ct2/show/NCT00848718) was conducted at 4 centers
(Royal Marsden NHS Foundation Trust, Sutton, Surrey,
UK; South Texas Accelerated Research Therapeutics
[START], Texas, USA; Princess Margaret Hospital, Toronto,
Ontario, Canada; H. Lee Moffitt Cancer Center and Re-
search Institute, Tampa, Florida, USA). The study was
conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice Guidelines of the International
Conference on Harmonization and was approved by
the Ethics Committees and Institutional Review
Boards at all study sites. All patients provided written
informed consent before any study procedures were
performed.Eligibility criteria
Patients 18 years or older with confirmed advanced solid
tumors were eligible if they had progressed after stan-
dard therapy, or if no standard therapy was available for
them; had Eastern Cooperative Oncology Group per-
formance status ≤1; surgery or chemotherapy within the
previous 4 weeks; ≤3 prior lines of cytotoxic therapies
(arms 1 and 2 only); residual toxicity from prior treat-
ment grade ≤1; adequate bone marrow, renal, and hepa-
tic function; and fasting serum glucose ≤1.1× the upper
limit of normal and hemoglobin A1c (HbA1c) ≤8%.
Patients were excluded if they were diabetic and on anti-
diabetic therapy, pregnant or breastfeeding, receiving
oral corticosteroids, had any condition(s) that would
impede drug ingestion or absorption, or had other sig-
nificant coexisting medical conditions.
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MK-2206 was initially administered PO every other day
(QOD) on days 1, 3, 5, and 7 (days 1-7) of a 21-day
cycle, in combination with intravenous (IV) carboplatin
(area under the curve 6.0 mg/mL [AUC 6]) over 1 hour
and IV paclitaxel 200 mg/m2 over 3 hours (arm 1;
Table 1); or IV docetaxel 75 mg/m2 over 1 hour (arm 2;
Table 1). MK-2206 was also administered QOD conti-
nuous with daily PO erlotinib 100 mg or 150 mg every
21 days; both MK-2206 and erlotinib were given on a
21-day cycle (arm 3; Table 1). Based on the MTD of
single-agent MK-2206 of 60 mg QOD, determined using
a modified 3 + 3 design [20], cohorts of 3 to 6 patients
were to be treated at preplanned MK-2206 dose levels of
45 mg and 60 mg, in combination with carboplatin and
paclitaxel (arm 1) or docetaxel (arm 2), or with erlotinib
(arm 3).
During dose escalation of the days 1–7 QOD dosing
schedule of MK-2206, emerging data led to the intro-
duction of 2 protocol amendments. First, data from
the same schedule in the first-in-human phase 1 study
demonstrated that MK-2206 had a long half-life (t1/2) of
60 to 80 hours. The tolerability of a QW schedule was
investigated and found to be acceptable with evidence of
PD activity [17]. Preclinical efficacy studies had also
demonstrated the antitumor effect of MK-2206 adminis-
tered either QW or 3 times per week with daily erlotinib
[19]. This suggested that continuous exposure with
MK-2206 may not be necessary with erlotinib and that






1 45 QOD Carboplatin (IV, AUC6, 1-hour
infusion) and paclitaxel




2 45 QOD Docetaxel (IV, 75 mg/m2,
1-hour infusion)




3 45 QOD* Erlotinib (oral, 100 mg, QD)
45 Erlotinib (oral, 150 mg, QD)
135 QW Erlotinib (oral, 100 mg, QD)
135 Erlotinib (oral, 150 mg, QD)
Abbreviations: IV intravenous, AUC6 area under the curve 6.0 mg/mL,
QD once daily.
aQOD = once every other day on days 1, 3, 5, and 7 of 21-day cycle, except
*: alternate day dosing on days 1–21; Q3W = once every 3 weeks on day 1 of
21-day cycle; QW = once weekly on days 1, 8, and 15 of 21-day cycle.combinations [18]. Second, 3 DLTs of febrile neutropenia
were reported at the first dose level of 45 mg MK-2206
QOD with IV docetaxel at 75 mg/m2. Consequently, 2
schedules (QW and Q3W) for MK-2206 were added to
the current study (Table 1). Fasted patients received
MK-2206 as 5-mg, 25-mg, or 200-mg tablets with che-
motherapy or erlotinib. The dose-escalation phase in all
schedules followed a toxicity probability interval approach,
where the aim was to target a dose with a DLT rate of
30% [20]. Patients could continue receiving single-agent
MK-2206 after completing chemotherapy or erlotinib
doses.
Safety
For all treatment schedules, safety assessments were con-
ducted at baseline and on days 1, 2, 3, 7, 15, and 21 of
cycle 1, and weekly in cycles 2 to 6. From cycle 7 onwards,
safety assessments were performed on day 1 of each cycle.
All patients had a history, physical examination including
full ophthalmologic assessment, electrocardiogram, hema-
tology and chemistry profiling, and urine analysis per-
formed at baseline. In addition to glucose monitoring,
serum c-peptide and whole blood HbA1c were measured
at baseline and monthly. Adverse events (AEs) and labora-
tory variables were assessed using the National Cancer
Institute Common Terminology Criteria for Adverse
Events (NCI-CTCAE) version 3.0 1.
A DLT was defined as any of the following occurring
during the first cycle of treatment: grade 4 neutropenia
lasting ≥7 days; grade 3 or 4 neutropenia with fever ≥38.5°C
and/or infection requiring therapy; grade 4 throm-
bocytopenia; any drug-related AE that led to dose modifi-
cation of MK-2206 or erlotinib; unresolved drug-related
toxicity regardless of grade that resulted in a 3-week or
longer delay of the start of cycle 2; persistent increase in
QTc interval (>60 ms from baseline and/or >500 ms); cli-
nically significant bradycardia; and any grade 3–5 nonhe-
matologic toxicity with the exception of, in the opinion of
the investigator, grade 3 nausea, vomiting, diarrhea, dehy-
dration or hyperglycemia in the setting of inadequate
compliance with supportive care treatment, alopecia, in-
adequately treated hypersensitivity reaction, and grade 3
elevated transaminases lasting 1 week or less.
Pharmacokinetic analyses
In arms 1 and 2, for days 1–7 QOD dosing, blood sampling
for MK-2206 PK was performed in cycle 1 on day 1 (pre-
dose, 2, 4, 6, 10, and 24 hours postdose), day 3 (48 hours
postdose), day 7 (predose and 4 hours postdose), and days
15 and 21 (same time as day 1 predose sampling). For the
Q3W schedule, samples were taken in cycle 1 on days 1 to
3 as per the QOD schedule, then on days 5, 7, 15, and in
cycle 2 on day 1. Blood samples were collected predose
and just before the end of the infusion for carboplatin,









ECOG PS, n (%)
0 22 (31)
1 49 (68)
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lysis. Another sample was taken 30 minutes into the infu-
sion of paclitaxel. These samples were archived for possible
future analysis to investigate if any unexpected toxicities
may have been as a result of a PK interaction. Docetaxel
PK samples were analyzed in view of the DLT of febrile
neutropenia observed in arm 2; however, PK parameters,
such as half-life (t1/2) or systemic exposure of paclitaxel,
docetaxel, carboplatin, and erlotinib, could not be evalu-
ated due to the sparse blood sampling design used in this
study.
In arm 3, for MK-2206 PK analysis in the QOD sche-
dule, sampling was performed in cycle 1 on days 1 and 3
as in arms 1 and 2, then on days 7 and 15 (predose), day
21 (predose, 2, 4, 6, and 10 hours postdose), and in cycle
2 on days 1 and 2 (predose). For QW dosing, samples
were taken in cycle 1 on day 1 (predose, 2, 4, 6, 10, and
24 hours postdose), day 3 (48 hours postdose), and day 5
(96 hours postdose), then on days 8 and 15 (predose).
This sampling schedule was repeated in cycle 2, except
for the day 15 predose sample, which was omitted. For
the QOD schedule, PK sampling for erlotinib was per-
formed in cycle 1 on day 1 (predose, 2 and 4 hours post-
dose) and day 21 (2 and 4 hours postdose); for the QW
schedule, sampling was performed in cycle 1 on day 1
(predose, 2 and 4 hours postdose) and in cycle 2 on day
1 (2 and 4 hours postdose). Blood samples for MK-2206
PK were obtained, processed, and analyzed as described
[18]. Blood samples were not analyzed for erlotinib con-
centrations as the potential for a marked drug-drug
interaction with erlotinib as a victim was considered to
be low as erlotinib is metabolized by both CYP3A and
CYP1A. In addition, the CYP3A induction or inhibition
potential of MK-2206 is low at the clinical concen-
trations achieved in this study, although the effect of
MK-2206 on CYP1A is unknown.Not recorded 1 (1)







Esophagus 3 (4.2)Biomarker studies
Circulating nucleic acids were analyzed for PIK3CA
(exons 9 and 20), KRAS (exons 2 and 3), and BRAF (exons
11 and 15) mutations. DNA extracted from whole blood
samples was subjected to real-time quantitative polyme-
rase chain reaction and spectrophotometric analysis as
part of the quality control process, as previously described
[21]. Mutation screening was performed using Surveyor
Nuclease (Transgenomic, Inc., Nebraska, USA).Parotid 3 (4.2)
SCLC 3 (4.2)
Othera 21 (29.2)
Abbreviations: SD standard deviation, ECOG Eastern Cooperative Oncology
Group, PS performance status, SCLC small cell lung cancer, SCC squamous
cell cancer.
aCervical, cholangiocarcinoma, gastric, mesothelioma, endothelial cell, bladder,
renal, sarcoma, SCC orbit, SCC vagina, SCC vulva, anal, tonsil, hard palate,
and vulva.Tumor response
Radiologic assessment (computed tomography [CT]
and/or magnetic resonance imaging [MRI] scans) of di-
sease status was performed at baseline and every 6
weeks according to Response Evaluation Criteria in
Solid Tumors (v1.0) [22]. Relevant markers were used toassess the effects of MK-2206 combination therapy on
various tumor types.
Results
Seventy-two patients were treated between April 2009 and
May 2012 (Table 2)—however, full accrual to the protocol
was suspended due to a change in the developmental
plans of MK-2206. In arm 1, 31 patients received a median
of 3 cycles (range 1–10) of combination therapy; 10 of
these patients went on to receive single-agent MK-2206
and completed a median of 4 cycles of treatment (range
1–15). In arm 2, 16 patients received a median of 3 cycles
(range 1–7) with 1 of these patients receiving 1 further
cycle of MK-2206 only. Another 25 patients received a
median of 5 cycles (range 1–12) in arm 3 of the study.
Dose-limiting toxicities and maximum tolerated dose
The MTD for all of the combinations could not be de-
termined according to the predefined protocol criteria
based on the number of patients enrolled at the time of
study discontinuation—in cases where higher dose levels
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(MAD) was determined. Dose-escalation levels and DLTs
are summarized in Table 3.
QOD dosing schedule
In arm 1, preplanned dose escalation from 45 to 60 mg
was achieved; DLTs were rash (1 of 5 at 45 mg and 1 of 4
at 60 mg; Figure 1A and 1B) and febrile neutropenia (2 of
4 at 60 mg). All episodes of rash were fully reversible
within 7 to 14 days after dose interruption and appro-
priate treatment. The MTD of MK-2206 was established
as 45 mg PO, when administered on the QOD dose
schedule on days 1, 3, 5, and 7, with carboplatin AUC 6
and paclitaxel 200 mg/m2. In arm 2, when MK-2206 was
administered at 45 mg days 1–7 QOD with docetaxel
75 mg/m2, 3 of 5 patients experienced a DLT of febrile
neutropenia. In arm 3, DLTs were rash and stomatitis
(2 of 8 at MK-2206 45 mg with erlotinib 100 mg; 1 of 3 at
MK-2206 45 mg with erlotinib 150 mg). The rash seen in
patients treated with MK-2206 and erlotinib was a com-
bination of the acneiform pattern seen with erlotinib and
the maculopapular pattern associated with MK-2206
(Figure 1C). Based on MK-2206 single-agent PK data and
the high incidence of febrile neutropenia in arm 2 with
docetaxel 75 mg/m2, a decision was made to reduce the
dose of docetaxel to 60 mg/m2 and investigate QW and
Q3W schedules.
Q3W and QW dosing schedules
In arms 1 and 2, dose escalation through 3 dose levels
administered Q3W (90, 135, and 200 mg) was achieved.Table 3 Dose schedules and dose-limiting toxicities of MK-22
Treatment arm MK-2206 dosing schedule






2 Docetaxel 75 mg/m2 45 mg QODb
Docetaxel 60 mg/m2 90 mg Q3W
135 mg Q3W
200 mg Q3W
3 Erlotinib 100 mg 45 mg QODc
135 mg QW
Erlotinib 150 mg 45 mg QODc
135 mg QW
Abbreviation: TCP thrombocytopenia.
a3 events in 2 patients.
bdays 1–7.
ccontinuous.In arm 1, DLTs were rash in 1 of 5 and 2 of 5 patients at
90 mg and 200 mg, respectively, and thrombocytopenia
in 1 of 5 patients at 135 mg. Therefore, the MTD of
Q3W MK-2206 dosing in combination with carboplatin
and paclitaxel was 135 mg. In arm 2, the only DLT was
tinnitus in 1 of 4 patients at MK-2206 200 mg with a re-
duced dose of docetaxel at 60 mg/m2. The combination
was not to be investigated further, so this dose level was
defined as the MAD; the MTD was not reached. In arm
3, 135 mg MK-2206 administered QW was tested with
erlotinib 100 mg and 150 mg, with 1 DLT of rash ob-
served in 5 patients at the higher dose level of erlotinib.
As DLTs were low (17%), the MTD of MK-2206 in this
combination was not reached. The MAD was defined as
MK-2206 135 mg QW with erlotinib 150 mg.
Safety and tolerability
Overall, the treatment combinations were well-tolerated,
with a low incidence of grade 3 or 4 AEs. The most com-
mon AEs were similar across the arms and schedules—
fatigue (68%), nausea (49%), rash (47%), diarrhea (44%),
anorexia (44%), alopecia (40%), vomiting (36%), stomatitis
(32%), and hyperglycemia (25%; 8% considered drug-
related). Hyperglycemia was transient, grade 1/2, and
largely associated with steroid premedication in arms 1
and 2. In arm 1, rash was observed more frequently with
the days 1–7 QOD dose schedule (40%) compared with
the Q3W schedule (25%). In arm 2, the frequency of fe-
brile neutropenia decreased with dose reduction of doce-
taxel and change to Q3W dosing for MK-2206. There
were no appreciable differences in the frequency of AEs06 in combination therapy
Evaluable patients Dose-limiting toxicities
5 1; rash












Figure 1 Patterns of drug induced rash. The typical rash
associated with MK-2206 was a widespread, reversible, generalized,
erythematous, maculopapular, non-acneiform rash (A and B). In arm 3,
some patients also demonstrated an acneiform rash affecting the head,
face, neck, and trunk, in addition to the maculopapular MK-2206 related
rash (C).
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however, chronic anorexia, fatigue, rash and diarrhea,
albeit at grade 1/2, were prominent. Table 4 summarizestreatment-related AEs observed by treatment arm and
NCI-CTCAE grade.
Pharmacokinetics
Pharmacokinetic data for MK-2206 were available from 70
patients: 30 from arm 1, 15 from arm 2, and 25 from arm
3. Across all treatment arms, AUC, maximum plasma
concentration (Cmax), and time to maximum concentra-
tion (Tmax) values following the first MK-2206 dose were
within ranges observed at the corresponding dose levels in
the single-agent phase 1 study [18]. However, due to insuf-
ficient PK sampling, steady-state exposure in combination
with either carboplatin and paclitaxel, docetaxel or erlo-
tinib could not be assessed. The apparent t1/2 of MK-2206
in combination with carboplatin and erlotinib was consis-
tent with that observed with monotherapy. Table 5 shows
the key PK parameters for MK-2206 at 45-mg, 60-mg,
90-mg, and 135-mg dose levels in this combination the-
rapy study after the first dose. The mean 48-hr plasma
concentrations of MK-2206 at the 45-mg QOD (arm 3),
60-mg QOD (arm 1), and 135-mg QW (arm 3) dose levels
were above 56.8 nM, at the last PK sampling time corre-
sponding to 70% AKT inhibition in the single-agent phase
1 study [18].
An analysis of docetaxel PK samples did not indicate a
PK cause for the higher-than-expected frequency of febrile
neutropenia DLTs in arm 2: the mean end-of-infusion
concentration value was 3.01 μg/mL. This is within the
range of mean values of 1.68 to 4.06 μg/mL reported in
the literature [23-25]. Paclitaxel, erlotinib, and carbo-
platin plasma samples were not assayed. Paclitaxel is
metabolized by CYP3A and CYP2C, while erlotinib is
metabolized primarily by CYP3A and CYP1A. The major
drug-metabolizing enzyme for docetaxel is CYP3A; thus,
docetaxel is vulnerable to CYP3A-mediated drug-drug in-
teractions, while carboplatin undergoes renal excretion
and hepatic metabolism equally, reducing its potential to
be a victim of CYP-mediated DDIs. MK-2206 is not a
significant inhibitor or inducer of major CYP enzymes
(IC50 >35 μM for CYP3A4, 2C9, and 2D6 inhibition, and
has insignificant effect on CYP3A mRNA and activity at
0.1 to 10 μM); therefore, MK-2206 is not expected to per-
petuate significant drug-drug interactions at the clinical
doses. MK-2206 is susceptible as a victim to CYP3A-
mediated drug-drug interaction as metabolism of MK-
2206 to oxidative metabolites in human microsomes is
mediated primarily by CYP3A. Exposure of MK-2206 after
co-administration with erlotinib did not suggest a sub-
stantial PK interaction of MK-2206 as a victim, although
attainment of a steady state of MK-2206 could not be
confirmed at the last PK sampling. Steady-state exposure
of MK-2206 in combination with either carboplatin and
paclitaxel or docetaxel are not available based on the study
design used.
Table 4 Treatment-related adverse events occurring in ≥20% of patients in any treatment arm with QOD and Q3W dosing schedules of MK-2206
Adverse event,
n (%)
Arm 1: carboplatin AUC 6; Arm 2: docetaxel Arm 3: erlotinib
Paclitaxel 200 mg/m2 75 mg/m2 60 mg/m2 100 mg and 150 mg
MK-2206 MK-2206 MK-2206 MK-2206 MK-2206 MK-2206























135 mgc (n = 6) 135 mgd
(n = 6)
Fatigue
Grade 1/2 5 (83) 6 (66) 4 (80) 4 (80) 1 (17) 4 (80) 3 (100) 2 (50) 4 (100) 4 (44) 3 (75) 4 (66) 3 (50)
Grade 3 0 0 0 1 (20) 0 0 0 0 0 1 (11) 0 0 1 (17)
Grade 4 0 0 0 0 0 0 0 0 0 0 0 0 0
Nausea
Grade 1/2 3 (50) 5 (55) 3 (60) 2 (40) 4 (66) 2 (40) 1 (33) 1 (25) 2 (50) 2 (22) 4 (100) 1 (17) 2 (33)
Grade 3 0 1 (11) 1 (20) 0 0 0 0 0 0 1 (11) 0 0 0
Grade 4 0 0 0 0 0 0 0 0 0 0 0 0 0
Rash
Grade 1/2 3 (50) 1 (11) 0 1 (20) 1 (17) 4 (80) 2 (66) 0 1 (25) 3 (33) 1 (25) 4 (66) 5 (83)
Grade 3 1 (17) 1 (11) 1 (20) 0 1 (17) 0 0 0 0 2 (22) 2 (50) 0 0
Grade 4 0 0 0 0 0 0 0 0 0 0 0 0 0
Decreased appetite
Grade 1/2 2 (33) 5 (55) 2 (40) 2 (40) 2 (33) 2 (40) 0 2 (50) 1 (25) 1 (11) 4 (100) 3 (50) 5 (83)
Grade 3 0 0 0 1 (20) 0 0 0 0 0 1 (11) 0 0 0
Grade 4 0 0 0 0 0 0 0 0 0 0 0 0 0
Diarrhea
Grade 1/2 1 (17) 4 (44) 2 (40) 1 (20) 2 (33) 1 (20) 2 (66) 0 2 (50) 4 (44) 3 (75) 4 (66) 5 (83)
Grade 3 0 0 0 0 0 0 0 0 0 1 (11) 0 0 0
Grade 4 0 0 0 0 0 0 0 0 0 0 0 0 0
Alopecia
Grade 1/2 4 (66) 6 (66) 5 (100) 4 (80) 2 (33) 3 (60) 1 (33) 1 (25) 2 (50) 0 0 1 (17) 0
Grade 3 0 0 0 0 0 0 0 0 0 0 0 1 (17) 0
Grade 4 0 0 0 0 0 0 0 0 0 0 0 0 0
Vomiting
Grade 1/2 1 (17) 3 (33) 0 3 (60) 4 (66) 3 (60) 1 (33) 1 (25) 1 (25) 4 (44) 1 (25) 1 (17) 0
Grade 3 0 1 (11) 1 (20) 0 0 0 0 0 0 0 0 1 (17) 0




















Table 4 Treatment-related adverse events occurring in ≥20% of patients in any treatment arm with QOD and Q3W dosing schedules of MK-2206 (Continued)
Anemia
Grade 1/2 1 (17) 1 (11) 2 (40) 1 (20) 1 (17) 2 (40) 0 1 (25) 1 (25) 2 (22) 0 0 2 (33)
Grade 3 0 3 (33) 1 (20) 1 (20) 0 0 0 0 0 0 0 1 (17) 0
Grade 4 1 (17) 1 (11) 0 1 (20) 0 0 0 0 0 0 0 0 1 (17)
Stomatitis
Grade 1/2 1 (17) 2 (22) 2 (40) 1 (20) 1 (17) 2 (40) 0 1 (25) 0 3 (33) 1 (25) 4 (66) 4 (66)
Grade 3 0 0 0 0 0 0 0 0 0 1 (11) 0 0 0
Grade 4 0 0 0 0 0 0 0 0 0 0 0 0 0
Neutropenia
Grade 1/2 0 0 0 0 0 0 0 0 0 0 0 0 0
Grade 3 0 2 (22) 2 (40) 1 (20) 1 (17) 1 (20) 1 (33) 0 0 0 0 0 0
Grade 4 1 (17) 3 (33) 2 (40) 2 (40) 0 2 (40) 1 (33) 0 1 (25) 0 0 0 0
Leukopenia
Grade 1/2 1 (17) 3 (33) 0 1 (20) 0 0 1 (33) 0 1 (25) 0 0 0 0
Grade 3 0 1 (11) 4 (80) 2 (40) 1 (17) 0 0 0 0 0 0 0 0
Grade 4 0 2 (22) 0 1 (20) 0 1 (20) 0 0 0 0 0 0 0
Thrombocytopen-ia
Grade 1/2 0 4 (44) 1 (20) 1 (20) 1 (17) 2 (40) 1 (33) 0 0 0 0 0 1 (17)
Grade 3 1 (17) 1 (11) 1 (20) 0 0 0 0 0 0 0 0 0 0
Grade 4 0 0 0 2 (40) 0 0 0 0 0 0 0 0 0
Pruritus
Grade 1/2 4 (66) 0 0 1 (20) 1 (17) 2 (40) 0 0 0 3 (33) 0 2 (33) 2 (33)
Grade 3 0 0 0 0 0 0 0 0 0 0 0 1 (17) 0
Grade 4 0 0 0 0 0 0 0 0 0 0 0 0 0
aMK-2206 QOD explored with docetaxel 75 mg/m2 only.






















Table 5 Pharmacokinetic parameters of MK-2206 after the first dose when administered in combination therapy





1 Carboplatin AUC 6
Paclitaxel 200 mg/m2
45 mg QOD 6 1630 ± 496 (30.4) 57.7 ± 13.8 (23.9) 4.0 (4.0–6.0) NA
60 mg QOD 8 2700 ± 619 (23.0) 88.3 ± 24.2 (27.4) 8.0 (6.0–10.0) NA
90 mg Q3W 5 4130 ± 1520 (36.6) 144 ± 57.0 (39.6) 6.0 (4.0–10.0) 79.5 ± 17.3
135 mg Q3W 6 7600 ± 1280 (15.3) 255 ± 50.9 (6.8) 8.0 (6.0–10.0) 73.0 ± 20.0
200 mg Q3W 5 9800 ± 2550 (25.9) 458 ± 268 (58.5) 4.0 (4.0–10.0) 74.7 ± 13.4
2 Docetaxel 75 mg/m2 45 mg QOD 5 1320 ± 395 (30.0) 42.9 ± 13.3 (30.9) 6.0 (4.0–10.0) NA
Docetaxel 60 mg/m2 90 mg Q3W 3 3000 ± 1250 (41.7) 106 ± 42.5 (40.2) 4.0 (4.0–10.0) 105.4 ± 15.0
135 mg Q3W 3 8090 ± 542 (6.7) 278 ± 35.5 (12.8) 6.0 (4.0–10.0) 106.1 ± 32.7
200 mg Q3W 4 7690 ± 1550 (20.1) 287 ± 67.6 (23.5) 6.0 (4.0–6.0) 86.9 ± 11.5
3 Erlotinib 100 mg 45 mg QOD 9 1460 ± 417 (28.6) 48.8 ± 11.2 (23.0) 6.0 (4.0–10.0) NA
135 mg QW 6 6420 ± 2760 (42.9) 212 ± 75.9 (35.8) 6.0 (2.0–6.0) 60.6 ± 6.6
Erlotinib 150 mg QD 45 mg QOD 4 2110 ± 637 (30.2) 65.6 ± 29.3 (44.6) 7.0 (4.0–24.0) NA
135 mg QW 6 6560 ± 2650 (40.2) 244 ± 84.2 (34.5) 4.0 (4.0–10.0) 50.2 ± 10.3
Abbreviations: AUC0-48h area under the curve from 0 to 48 hours, Cmaxmaximum concentration, Tmax time to maximum concentration, Q21 every 21 days, NA not
available, SD standard deviation.
aMean ± SD (coefficient of variation%).
bMedian (range).
cHarmonic mean ± pseudo SD.
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Sixty patients were evaluable for response (arm 1, n = 24;
arm 2, n = 13; arm 3, n = 23). In arm 1, a complete
response was observed in 1 patient with squamous cell
carcinoma (SCC) of the orbit who had progressed through
previous cisplatin, cetuximab, and 5-fluorouracil therapy
(Figure 2A). Four patients treated on both the days 1–7
QOD and Q3W schedules in arm 1 had confirmed partial
responses (PR; melanoma, neuroendocrine prostate, endo-
metrial, and cervical), and 2 patients had unconfirmed
PRs (SCC of the head and neck, and gastric; Figure 2B).
The patient with neuroendocrine prostate cancer had pre-
viously had a best response of stable disease (SD) with car-
boplatin and etoposide, while the patient with endometrial
cancer had demonstrated SD with carboplatin and pacli-
taxel. The median duration of PR was 11 months (range
2–21 months). Six patients demonstrated SD lasting at
least 6 months (median duration of SD was 7 months
[range 1–13]). One patient with non-small cell lung can-
cer (NSCLC) treated Q3W with MK-2206 and docetaxel
demonstrated a confirmed PR; this patient had received 2
prior lines of platinum-based chemotherapy and erlotinib.
Figures 2C and 2D illustrate the overall best responses in
evaluable patients in arms 2 and 3, respectively. Biomarker
analysis was conducted on 68 patients, of whom 7 tested
positive for mutations. Four patients carried a PIK3CA
mutation (exon 20) and 3 carried a KRAS (exon 12) muta-
tion. Patients harboring PIK3CA mutations demonstrated
SD ranging from 1.7 to 5.8 months, whereas patients with
KRAS mutations had SD ranging from 1.4 to 3.0 months.Discussion
Our study demonstrates that MK-2206 in combination
with standard cytotoxic chemotherapies can be safely
administered to patients with advanced solid tumors, at
doses demonstrating antitumor activity. The combinations
were tolerable, with the main DLTs being rash and febrile
neutropenia. The most common AEs were fatigue, nausea,
rash, diarrhea, and anorexia, with no apparent exacerba-
tion of toxicities associated with standard agents. Of note,
drug-related hyperglycemia—an expected effect of AKT
inhibition—was evident in <10% of patients, a rate similar
to the single-agent phase 1 study [18].
At the 45-mg dose level in all schedules, mean Ctrough
for MK-2206 was >56.8 nM, corresponding with 70%
AKT inhibition in the single-agent study [18]. The MTD
and recommended schedule of MK-2206 in combination
with carboplatin AUC 6 and paclitaxel 200 mg/m2 were
defined as 135 mg Q3W. With docetaxel, the MTD of
MK-2206 was not reached, but the MAD of MK-2206 was
defined as 200 mg Q3W with docetaxel 60 mg/m2. The
dose escalation of this combination was not further inves-
tigated due to a high neutropenia rate when docetaxel was
administered at 75 mg/m2 and the lack of clinical activity;
this 60% rate of febrile neutropenia may be a reflection of
the small patient numbers. However, it was felt that these
2 factors would likely limit the future use of this combi-
nation. The MK-2206 plus erlotinib combination reached
the MAD of 135 mg QW and 150 mg daily, respectively.
Based on emerging data from the monotherapy phase 1
study where MK-2206 MTD is limited to 200 mg QW, as
Figure 2 Best radiological response (RECIST) associated with
MK-2206 combinations. CT scan slices demonstrating a CR in a
male patient with SCC of the orbit (A). Waterfall plots of the best
responses seen in all evaluable patients in arm 1, carboplatin and
paclitaxel (B), arm 2, docetaxel (C), and arm 3, erlotinib (D). In arm 1, 6
patients treated in both schedules of MK-2206 with carboplatin and
paclitaxel chemotherapy had PRs: with 4 of these being confirmed:
melanoma (n = 1, 21-month duration—8 months while on study and
13 months after study discontinuation), neuroendocrine prostate (n = 1,
6-month duration), cervical (n = 1, 6-month duration), and endometrial
(n = 1, 4-month duration); and 2 were unconfirmed: gastric (n = 1,
2-month duration) and SCC of the head and neck (n = 1, 2-month
duration). In arm 2, a female patient with NSCLC who had progressed
through pemetrexed-platinum and erlotinib achieved a PR with
MK-2206 200 mg lasting 6 months. The patient withdrew from the
study due to docetaxel-related toxicities, before documentation of
progressive disease. No objective responses were observed in arm 3:
the best response was SD lasting 7 and 6 months in a male patient
with NSCLC and a patient with cervical cancer, respectively. Dashed
lines indicate the threshold for PD (≥20% increase) and PR (≥30%
decrease) based on the change in the sum of target lesions from
baseline by Response Evaluation Criteria in Solid Tumors guidelines.
CT = computed tomography; CR = complete response; SCC = squamous
cell carcinoma; PR = particle response; NSCLC = non-small cell lung
cancer; SD = stable disease; PD = progressive disease; QOD = alternate
days; Q3W = every 3 weeks; QW = week.
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agents, it was decided that the risk of further dose esca-
lation outweighed the potential benefit and therefore the
MAD is the recommended phase 2 dose (RP2D).
The anticancer activity of the combinations, particularly
MK-2206/carboplatin and paclitaxel, was notable, with
durable responses seen in some patients previously ex-
posed to platinum and taxane compounds. There was no
correlation between responses or prolonged SD with mu-
tations activating the PI3K pathway, although 1 metastatic
breast cancer patient harboring a PIK3CA mutation (exon
20), previously treated with 3 lines of chemotherapy and 1
line of hormonal therapy with progressive disease, demon-
strated SD for 4 months. Phase 1 studies of MK-2206 with
paclitaxel in breast cancer and with paclitaxel and tra-
stuzumab in patients overexpressing human epidermal
growth factor receptor-2 are underway.
Preclinical data in NSCLC cell lines suggest a strong
rationale for the combination of MK-2206 and erlotinib
[19,26]. In our study, most patients with NSCLC (n = 5)
were treated on the less well-tolerated and possibly sub-
optimal QOD schedule. Using the QW schedule, only 1
patient with NSCLC, who achieved a best response of
SD lasting 7 months, was included. The antitumor acti-
vity of this combination is likely to be best determined
in selected patients with molecularly characterized tu-
mors. The combination is currently being investigated in
an open-label, phase 2 trial of patients with advanced
NSCLC. A phase 1 study is also investigating the com-
bination of MK-2206 with gefitinib in patients who
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factor receptor (erlotinib or gefitinib) inhibitor. Previous
results suggest that tumors with KRAS mutations are
more effectively inhibited with a combination of an AKT
and a MEK inhibitor [27,28]. These combinations are
being further explored in the Biomarker Integrated
Targeted Therapy Program (BATTLE-2), where recruit-
ment into different arms is based on the molecular sta-
tus of the patient’s tumor [29].
Based on the early evidence of clinical activity, larger
phase 2 randomized studies are underway in various
tumor types to test whether the addition of MK-2206 to
standard treatment enhances antitumor effects. One such
study is assessing the combination with the anti-androgen
bicalutamide, where patients with prostate cancer are
randomized to receive bicalutamide with or without
MK-2206. Dysregulation of the PI3K pathway is one of
the most frequent mechanisms of resistance to conven-
tional anti-androgen therapy [30], highlighting a need for
effective agents that could inhibit cell signalling via this
pathway. Another study is investigating the efficacy of the
addition of MK-2206 to anastrazole or fulvestrant, and
comparing these combinations to either agent alone in
women with metastatic breast cancer.
In conclusion, our study shows that MK-2206, using a
QOD, QW, or Q3W dosing schedule in combination
with carboplatin and paclitaxel, docetaxel, or erlotinib,
was well-tolerated at doses that inhibit AKT signaling.
Phase 2 programs are underway to further investigate
the combination of MK-2206 with carboplatin and pacli-
taxel or erlotinib, which along with other randomized
phase 2 studies should provide a broad clinical profile of
MK-2206 in combination with other standard cytotoxic
or targeted treatment options.
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